Roundtable Discussion — Modern Management of Multiple Myeloma: The Australian Perspective

Dates:: 2026-05-04
Organizer:: International Academy for Clinical Hematology (IACH)
Location:: Online webinar (Zoom)
Specialty:: Hematology / Oncology
Format:: Online

A live IACH (International Academy for Clinical Hematology) roundtable discussion on the Modern Management of Multiple Myeloma — The Australian Perspective, bringing together leading Australian haematologists and IACH President Prof. Mohamad Mohty. Date: Monday, 4 May 2026 Time: 10:00 AM CET / 6:00 PM Sydney (AEST) Format: Online webinar (Zoom) — Free registration Faculty / Panel: Prof. P. Joy Ho

Full details and registration

This event has ended

Concluded 4 months ago · May 4, 2026

Browse upcoming

Roundtable Discussion — Modern Management of Multiple Myeloma: The Australian Perspective

1 / 1

1 photos · tap to enlarge

Hematology / Oncology Webinar Online

May 4 – May 4, 2026

Online · Online webinar (Zoom)

Roundtable Discussion — Modern Management of Multiple Myeloma: The Australian Perspective

International Academy for Clinical Hematology (IACH)

Listed 30 Apr 2026

Add to Calendar

About this event

A live IACH (International Academy for Clinical Hematology) roundtable discussion on the Modern Management of Multiple Myeloma — The Australian Perspective, bringing together leading Australian haematologists and IACH President Prof. Mohamad Mohty.

Date: Monday, 4 May 2026 Time: 10:00 AM CET / 6:00 PM Sydney (AEST) Format: Online webinar (Zoom) — Free registration

Faculty / Panel:

Prof. P. Joy Ho — Royal Prince Alfred Hospital, University of Sydney
Dr. Wojt Janowski — Calvary Mater Newcastle
A/Prof. Cindy Lee — Royal Adelaide & Queen Elizabeth Hospitals
Prof. H. Miles Prince — Epworth HealthCare, Melbourne / Monash University
Prof. Hang Quach — St Vincent's Hospital Melbourne, University of Melbourne
Prof. Mohamad Mohty (Chair) — Saint-Antoine Hospital, Sorbonne University, Paris

Discussions will cover newly-diagnosed and relapsed/refractory myeloma, the role of bispecific antibodies and CAR-T, and how Australian practice integrates the latest evidence.